Rockefeller Capital Management’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.39K Buy
204
+200
+5,000% +$4.96K ﹤0.01% 4417
2026
Q2
$85 Hold
4
– – ﹤0.01% 4692
2026
Q1
$87 Buy
+4
New +$89 ﹤0.01% 4640
2022
Q2
– Sell
-20
Closed – – 4241
2022
Q1
$0 Hold
20
– – ﹤0.01% 3966
2021
Q4
$0 Hold
20
– – ﹤0.01% 3873
2021
Q3
$0 Hold
20
– – ﹤0.01% 3753
2021
Q2
$0 Hold
20
– – ﹤0.01% 3516
2021
Q1
$0 Buy
+20
New +$497 ﹤0.01% 3315

Other funds holding IMNM

Rockefeller Capital Management's IMNM Position: Q3 2026 in Review

Rockefeller Capital Management increased its Immunome (IMNM) stake by 5,000% in Q3 2026, buying an estimated $4.96K and bringing the position to 204 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #4417.

Rockefeller Capital Management first reported a position in IMNM in Q1 2021 and has held it in 8 quarters since. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • Rockefeller Capital Management held 204 shares of Immunome worth $4.39K as of Q3 2026.
  • Rockefeller Capital Management bought 200 Immunome shares in Q3 2026, an estimated $4.96K.
  • Immunome made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4417 holding.
  • Rockefeller Capital Management first reported a position in Immunome in Q1 2021 and has held it in 8 quarters since.
  • 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.